Fem-Matrix
Natural health product licensed in Canada
- Licence holder
- Cyto-Matrix Inc.
- NPN or DIN-HM
- 80055610
- Status
- Active licence
- Licence date
- 13 November 2014
- Revision date
- 20 March 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Dioscorea villosa L.: Les matières premières végétales doivent avoir subi les étapes traditionnelles d'épluchage, de lavage et de traitement thermique. L'absence d'alcaloïdes et de composés cyanogènes doit être démontrée par des bulletins d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Trifolium pratense L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| (2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one Source : Citrus aurantium - fruit | 125 mg | Not calculated |
| Actaea racemosa Source : Racine et rhizome Extract : Matériel brut sec Extraction ratio : 6:1 Dry plant equivalent : 300 mg Potency : 2.5 % Triterpene Glycosides | 50 mg | Not calculated |
| Dioscorea villosa Source : Racine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 mg | 50 mg | Not calculated |
| Angelica sinensis Source : Racine Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 240 mg Potency : 1 % ligustilide | 60 mg | Not calculated |
| 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one Source : Styphnolobium japonicum - fleur | 125 mg | Not calculated |
| Vitex agnus-castus Source : Fruit Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 mg | 50 mg | Not calculated |
| Hypericum perforatum Source : Sommité Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 300 mg Potency : 0.3 % hypericin | 30 mg | Not calculated |
| Trifolium pratense Source : Fleur Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 200 mg | 20 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Cellulose microcristalline, Dioxyde de silicium, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Black Cohosh is used in Herbal Medicine to help relieve symptoms associated with menopause. Black Cohosh is used in Herbal Medicine to help relieve premenstrual symptoms. Black Cohosh is traditionally used in Herbal Medicine to help relieve the pain associated with menstruation. Wild Yam is traditionally used in Herbal Medicine as an antispasmotic to relieve abdominal and menstrual pain.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80055610
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging